NEW YORK, Aug. 9 – Academic researchers collaborating with Montreal-based SignalGene have identified a genetic variation that may cut the risk of developing breast cancer by 50 percent, the company said on Thursday. 

Using population genetics to study 716 Caucasian women of French Canadian descent, researchers at Université Laval and several hospitals in Quebec City found two versions of a gene that encode for an androgen receptor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.